OR WAIT null SECS
Emmes announced that it has acquired Casimir. Terms of the transaction were not disclosed.
Emmes' acquisition of Casimir will further accelerate its strategic focus on rare disease research, building on Emmes' acquisition of Orphan Reach last year. With Casimir's proprietary clinical outcomes technology, Emmes will be even better positioned in rare and orphan disease clinical research and drug development.
Read more about the acquisition here.